What ever happened to FDAMA Section 114? A look back after 10 years.
نویسنده
چکیده
ARTICLE TEXT The United States Food and Drug Modernization Act (FDAMA) took effect in 1998 with high expectations from the pharmacoeconomics community. Section 114 of the Act stipulated the conditions under which drug companies could promote health economic information to their managed care customers, and seemingly would make it easier for pharmacoeconomic modelers and outcomes researchers to communicate their work. A small survey (n = 36) of pharmaceutical and managed care representatives, conducted in the months after Section 114's enactment, found that most respondents believed the Act would encourage companies to present more health economic data to managed care plans [1].
منابع مشابه
WOLFS M Creating a Little Big Bang on
ANKIND HAS ALWAYS been fascinated with looking back in time. Historians and archaeologists use historical records and artifacts to trace back the evolution of mankind. Biologists use evolutionary theory to describe the development of life on Earth. The Earth is relatively young by astronomical standards, about 4.6 billion years, and the Universe is even older. It is believed that the Universe w...
متن کاملDrug company advertising in medical journals about the health-economic advantages of their products for 2000-2006 versus 1990-1999.
BACKGROUND Section 114 of the 1997 Food and Drug Administration Modernization Act (FDAMA) effective February 19, 1998, permitted some additional flexibility for drug companies to provide "health care economic information" to "a formulary committee or other similar entity" and may have caused a decline in economic messages used in print advertisements in medical journals. We previously investiga...
متن کاملPediatric testing of prescription drugs: the Food and Drug Administration's carrot and stick for the pharmaceutical industry.
Introduction........................................................................................ 740 I. Pediatric Testing: A Historical Perspective of the “Therapeutic Orphan” ............................................................. 746 A. Past Attempts to Acquire Pediatric Labeling.................... 746 B. FDAMA Section 111—Pediatric Exclusivity...................... 749 C. FDA’s Ma...
متن کاملWhat ain’t mathematics education?!
Abstract: In 1996 at the first Iranian Mathematics Education Conference (IMEC1) that was held in Isfahan. I obliged myself as a mathematics educator, to inform the mathematics community at large by presenting a paper entitled “what is mathematics education?” to pave the way for the establishment of the master program of mathematics education in Iran. Now, after 16 years, we need to reflect on t...
متن کاملبررسی مقایسه‌ای شیوع کمر درد و عوامل مؤثر بر آن در دندانپزشکان و داروسازان مرد ایرانی
Background and Aims: Regarding the diversity of reported low- back pain among dentists in different countries and lack of control group in most of the previous studies, the purpose of this study was to compare low- back pain and related risk factors between male general dentists and pharmacists to determine the relation between dentistry and development of low back pain. Materials and Methods: ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
دوره 12 2 شماره
صفحات -
تاریخ انتشار 2009